Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies

Merck & Co has put the brakes on enrolment into two Phase III trials of Keytruda in multiple myeloma to allow it to investigate more deaths in the groups receiving the anti-PD1 product.